Jagdish Agrawal, a promoter of Ishita Drugs & Industries Ltd , has acquired additional equity shares in the pharmaceutical company through open market transactions. The acquisition was formally disclosed to BSE Limited on December 30, 2025, in compliance with SEBI regulations governing substantial acquisition of shares.

Transaction Details

The share acquisition transaction involved specific parameters that demonstrate the promoter's continued investment in the company:

Shareholding Pattern Changes

The acquisition resulted in a marginal increase in Agrawal's ownership stake in the company. The following table illustrates the changes in his shareholding pattern:

The transaction represents a minimal increase in the promoter's stake, with the percentage holding rising by just 0.01 percentage points.

Company Capital Structure

Ishita Drugs & Industries Ltd maintains a stable capital structure following this transaction. The company's equity share capital remained unchanged at ₹2.99 crores, consisting of 2,990,300 equity shares with a face value of ₹10.00 each. The total diluted share capital also remains at the same level, indicating no outstanding convertible securities or warrants.

Regulatory Compliance

The disclosure was made under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Agrawal, identified as a promoter of the company, fulfilled the mandatory reporting requirements by submitting the necessary documentation to BSE Limited within the prescribed timeframe. The company's shares are listed on BSE Limited under scrip code 524400.

Ishita Drugs & Industries , a pharmaceutical company, has witnessed continued investment from Ishita Pharmaceuticals, a related party, which has further increased its shareholding in the company. Following an earlier acquisition, Ishita Pharmaceuticals has made an additional purchase, demonstrating sustained interest in the target company.

Latest Transaction Details

In the most recent transaction dated December 08, 2025, Ishita Pharmaceuticals acquired an additional 560 shares of Ishita Drugs & Industries through open market purchase. Each share carries a face value of Rs. 10.00, representing a 0.02% increase in shareholding.

Updated Shareholding Pattern

The cumulative effect of Ishita Pharmaceuticals' investments has resulted in a progressive increase in its stake in Ishita Drugs & Industries.

Company Capital Structure

The equity share capital of Ishita Drugs & Industries remains unchanged at Rs. 29,903,000.00, comprising 2,990,300 shares with a face value of Rs. 10.00 each. The recent acquisition does not impact the overall capital structure of the company.

Regulatory Compliance and Documentation

In accordance with SEBI regulations, specifically Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, both companies have filed the necessary disclosures. Ishita Drugs & Industries communicated the transaction details to BSE Limited on December 10, 2025, while Ishita Pharmaceuticals submitted its disclosure on December 09, 2025.

Market Implications

The progressive increase in shareholding by Ishita Pharmaceuticals, from an initial entry to now holding 1.02% of voting rights, indicates a strategic interest in Ishita Drugs & Industries. As related parties, this continued investment pattern suggests potential for enhanced collaboration and strategic alignment between the two pharmaceutical entities. The company is listed on BSE Limited under scrip code 524400.